The 7 analysts offering 12-month price forecasts for Avita Therapeutics Inc have a median target of 41.00, with a high estimate of 60.00 and a low estimate of 5.88. The median estimate represents a +75.14% increase from the last price of 23.41.
The current consensus among 8 polled investment analysts is to Buy stock in Avita Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.27
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.